These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 34142533)

  • 21. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-based lead optimization of herbal medicine rutin for inhibiting SARS-CoV-2's main protease.
    Huynh T; Wang H; Luan B
    Phys Chem Chem Phys; 2020 Nov; 22(43):25335-25343. PubMed ID: 33140777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach.
    Sabarimurugan S; Purushothaman I; Swaminathan R; Dharmarajan A; Warrier S; Kothandan S
    Acta Virol; 2021; 65(2):160-172. PubMed ID: 34130467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of new anti-nCoV drug chemical compounds from Indian spices exploiting SARS-CoV-2 main protease as target.
    Kundu D; Selvaraj C; Singh SK; Dubey VK
    J Biomol Struct Dyn; 2021 Jun; 39(9):3428-3434. PubMed ID: 32362243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2
    Khan SA; Zia K; Ashraf S; Uddin R; Ul-Haq Z
    J Biomol Struct Dyn; 2021 Apr; 39(7):2607-2616. PubMed ID: 32238094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding the binding affinity of noscapines with protease of SARS-CoV-2 for COVID-19 using MD simulations at different temperatures.
    Kumar D; Kumari K; Jayaraj A; Kumar V; Kumar RV; Dass SK; Chandra R; Singh P
    J Biomol Struct Dyn; 2021 Apr; 39(7):2659-2672. PubMed ID: 32362235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analyzing 3D structures of the SARS-CoV-2 main protease reveals structural features of ligand binding for COVID-19 drug discovery.
    Xu L; Chen R; Liu J; Patterson TA; Hong H
    Drug Discov Today; 2023 Oct; 28(10):103727. PubMed ID: 37516343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Marine algal antagonists targeting 3CL protease and spike glycoprotein of SARS-CoV-2: a computational approach for anti-COVID-19 drug discovery.
    Arunkumar M; Gunaseelan S; Kubendran Aravind M; Mohankumar V; Anupam P; Harikrishnan M; Siva A; Ashokkumar B; Varalakshmi P
    J Biomol Struct Dyn; 2022; 40(19):8961-8988. PubMed ID: 34014150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of polyphenols from
    Ghosh R; Chakraborty A; Biswas A; Chowdhuri S
    J Biomol Struct Dyn; 2021 Oct; 39(17):6747-6760. PubMed ID: 32762411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AI-Driven Discovery of SARS-CoV-2 Main Protease Fragment-like Inhibitors with Antiviral Activity
    Saramago LC; Santana MV; Gomes BF; Dantas RF; Senger MR; Oliveira Borges PH; Ferreira VNDS; Dos Santos Rosa A; Tucci AR; Dias Miranda M; Lukacik P; Strain-Damerell C; Owen CD; Walsh MA; Ferreira SB; Silva-Junior FP
    J Chem Inf Model; 2023 May; 63(9):2866-2880. PubMed ID: 37058135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening of potent phytochemical inhibitors against SARS-CoV-2 protease and its two Asian mutants.
    Muhammad I; Rahman N; Gul-E-Nayab ; Niaz S; Basharat Z; Rastrelli L; Jayanthi S; Efferth T; Khan H
    Comput Biol Med; 2021 Jun; 133():104362. PubMed ID: 33894500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Virtual screening, ADMET prediction and dynamics simulation of potential compounds targeting the main protease of SARS-CoV-2.
    Yadav R; Imran M; Dhamija P; Chaurasia DK; Handu S
    J Biomol Struct Dyn; 2021 Oct; 39(17):6617-6632. PubMed ID: 32715956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Computational Screening of Inhibitory Compounds for SARS-Cov-2 3CL Protease with a Database Consisting of Approved and Investigational Chemicals.
    Miwa K; Guo Y; Hata M; Yamamoto N; Hoshino T
    Chem Pharm Bull (Tokyo); 2023; 71(5):360-367. PubMed ID: 37121686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in the Development of SARS-CoV-2 Mpro Inhibitors.
    Agost-Beltrán L; de la Hoz-Rodríguez S; Bou-Iserte L; Rodríguez S; Fernández-de-la-Pradilla A; González FV
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiviral drug discovery by targeting the SARS-CoV-2 polyprotein processing by inhibition of the main protease.
    Kandeel M; Kim J; Fayez M; Kitade Y; Kwon HJ
    PeerJ; 2022; 10():e12929. PubMed ID: 35186496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Computational discovery of small drug-like compounds as potential inhibitors of SARS-CoV-2 main protease.
    Andrianov AM; Kornoushenko YV; Karpenko AD; Bosko IP; Tuzikov AV
    J Biomol Struct Dyn; 2021 Sep; 39(15):5779-5791. PubMed ID: 32662333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.
    Yamaya M; Nishimura H; Deng X; Kikuchi A; Nagatomi R
    Tohoku J Exp Med; 2020 May; 251(1):27-30. PubMed ID: 32448818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In-silico studies of inhibitory compounds against protease enzymes of SARS-CoV-2.
    Khan S; Nasrullah ; Hussain A; Asif M; Sattar FA; Audhal FA; Qadir MI; Hamdard MH
    Medicine (Baltimore); 2023 Feb; 102(6):e31318. PubMed ID: 36820539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In silico study of alkaloids with quercetin nucleus for inhibition of SARS-CoV-2 protease and receptor cell protease.
    Mohebbi A; Eskandarzadeh M; Zangi H; Fatehi M
    PLoS One; 2024; 19(4):e0298201. PubMed ID: 38626042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In-silico evaluation of natural alkaloids against the main protease and spike glycoprotein as potential therapeutic agents for SARS-CoV-2.
    Shah M; Yamin R; Ahmad I; Wu G; Jahangir Z; Shamim A; Nawaz H; Nishan U; Ullah R; Ali EA; Sheheryar ; Chen K
    PLoS One; 2024; 19(1):e0294769. PubMed ID: 38175855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.